Literature DB >> 19693328

Origins of epilepsy in fragile X syndrome.

Paul J Hagerman1, Carl E Stafstrom.   

Abstract

Fragile X syndrome is the leading heritable form of cognitive impairment and the leading known monogenic disorder associated with autism. Roughly one-quarter of children with this disorder have seizures, most of which are relatively benign and are resolved beyond childhood. Because of the prevalence of fragile X syndrome, numerous animal models have been developed and electrophysiological studies have taken place to investigate its pathogenesis. The investigations have yielded a wealth of information regarding the synaptic dysfunction that underlies the hyperexcitability and epileptiform features associated with this disorder.

Entities:  

Year:  2009        PMID: 19693328      PMCID: PMC2728488          DOI: 10.1111/j.1535-7511.2009.01309.x

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN: 1535-7511            Impact factor:   7.500


  49 in total

Review 1.  Screening for fragile X syndrome: a literature review and modelling study.

Authors:  F J Song; P Barton; V Sleightholme; G L Yao; A Fry-Smith
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

Review 2.  Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function.

Authors:  Gary J Bassell; Stephen T Warren
Journal:  Neuron       Date:  2008-10-23       Impact factor: 17.173

3.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

4.  Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation.

Authors:  I J Weiler; S A Irwin; A Y Klintsova; C M Spencer; A D Brazelton; K Miyashiro; T A Comery; B Patel; J Eberwine; W T Greenough
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurophysiol       Date:  2006-02-01       Impact factor: 2.714

6.  Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors.

Authors:  Walter E Kaufmann; Ranon Cortell; Alice S M Kau; Irena Bukelis; Elaine Tierney; Robert M Gray; Christiane Cox; George T Capone; Pia Stanard
Journal:  Am J Med Genet A       Date:  2004-09-01       Impact factor: 2.802

Review 7.  The FMR1 gene and fragile X-associated tremor/ataxia syndrome.

Authors:  J R Brouwer; R Willemsen; B A Oostra
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-09-05       Impact factor: 3.568

Review 8.  Phenotypic variation and FMRP levels in fragile X.

Authors:  Danuta Z Loesch; Richard M Huggins; Randi J Hagerman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

Review 9.  Lessons from fragile X regarding neurobiology, autism, and neurodegeneration.

Authors:  Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-02       Impact factor: 2.225

10.  Limbic epileptogenesis in a mouse model of fragile X syndrome.

Authors:  Li-Feng Qiu; Ting-Jia Lu; Xiao-Ling Hu; Yong-Hong Yi; Wei-Ping Liao; Zhi-Qi Xiong
Journal:  Cereb Cortex       Date:  2008-10-01       Impact factor: 5.357

View more
  43 in total

Review 1.  Fragile X syndrome: the GABAergic system and circuit dysfunction.

Authors:  Scott M Paluszkiewicz; Brandon S Martin; Molly M Huntsman
Journal:  Dev Neurosci       Date:  2011-09-21       Impact factor: 2.984

2.  Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder.

Authors:  Weerasak Chonchaiya; Jacky Au; Andrea Schneider; David Hessl; Susan W Harris; Meredith Laird; Yi Mu; Flora Tassone; Danh V Nguyen; Randi J Hagerman
Journal:  Hum Genet       Date:  2011-10-15       Impact factor: 4.132

3.  Decreased surface expression of the δ subunit of the GABAA receptor contributes to reduced tonic inhibition in dentate granule cells in a mouse model of fragile X syndrome.

Authors:  Nianhui Zhang; Zechun Peng; Xiaoping Tong; A Kerstin Lindemeyer; Yliana Cetina; Christine S Huang; Richard W Olsen; Thomas S Otis; Carolyn R Houser
Journal:  Exp Neurol       Date:  2017-08-16       Impact factor: 5.330

Review 4.  Epigenetic mechanisms underlying human epileptic disorders and the process of epileptogenesis.

Authors:  Irfan A Qureshi; Mark F Mehler
Journal:  Neurobiol Dis       Date:  2010-02-24       Impact factor: 5.996

Review 5.  mTOR Inhibitors in Children: Current Indications and Future Directions in Neurology.

Authors:  Anna Jeong; Michael Wong
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

6.  Aging in fragile X syndrome.

Authors:  Agustini Utari; Evan Adams; Elizabeth Berry-Kravis; Alyssa Chavez; Felicia Scaggs; Lily Ngotran; Antoniya Boyd; David Hessl; Louise W Gane; Flora Tassone; Nicole Tartaglia; Maureen A Leehey; Randi J Hagerman
Journal:  J Neurodev Disord       Date:  2010-05-12       Impact factor: 4.025

Review 7.  Emerging roles of astrocytes in neural circuit development.

Authors:  Laura E Clarke; Ben A Barres
Journal:  Nat Rev Neurosci       Date:  2013-04-18       Impact factor: 34.870

Review 8.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

Review 9.  Fragile X syndrome: A review of clinical management.

Authors:  Reymundo Lozano; Atoosa Azarang; Tanaporn Wilaisakditipakorn; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2016-08

10.  Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system.

Authors:  Ryan H Lee; Elizabeth A Mills; Neil Schwartz; Mark R Bell; Katherine E Deeg; Edward S Ruthazer; Nicholas Marsh-Armstrong; Carlos D Aizenman
Journal:  Neural Dev       Date:  2010-01-12       Impact factor: 3.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.